全文获取类型
收费全文 | 24458篇 |
免费 | 2267篇 |
国内免费 | 912篇 |
专业分类
耳鼻咽喉 | 88篇 |
儿科学 | 334篇 |
妇产科学 | 334篇 |
基础医学 | 2098篇 |
口腔科学 | 306篇 |
临床医学 | 1769篇 |
内科学 | 5373篇 |
皮肤病学 | 440篇 |
神经病学 | 1509篇 |
特种医学 | 202篇 |
外国民族医学 | 6篇 |
外科学 | 1765篇 |
综合类 | 2342篇 |
现状与发展 | 16篇 |
预防医学 | 408篇 |
眼科学 | 329篇 |
药学 | 5877篇 |
6篇 | |
中国医学 | 699篇 |
肿瘤学 | 3736篇 |
出版年
2024年 | 49篇 |
2023年 | 551篇 |
2022年 | 615篇 |
2021年 | 1309篇 |
2020年 | 1083篇 |
2019年 | 980篇 |
2018年 | 981篇 |
2017年 | 978篇 |
2016年 | 866篇 |
2015年 | 1040篇 |
2014年 | 1579篇 |
2013年 | 2440篇 |
2012年 | 1392篇 |
2011年 | 1605篇 |
2010年 | 1230篇 |
2009年 | 1283篇 |
2008年 | 1346篇 |
2007年 | 1163篇 |
2006年 | 1097篇 |
2005年 | 968篇 |
2004年 | 776篇 |
2003年 | 664篇 |
2002年 | 513篇 |
2001年 | 407篇 |
2000年 | 317篇 |
1999年 | 284篇 |
1998年 | 236篇 |
1997年 | 239篇 |
1996年 | 204篇 |
1995年 | 185篇 |
1994年 | 141篇 |
1993年 | 127篇 |
1992年 | 96篇 |
1991年 | 110篇 |
1990年 | 116篇 |
1989年 | 87篇 |
1988年 | 76篇 |
1987年 | 42篇 |
1986年 | 52篇 |
1985年 | 78篇 |
1984年 | 67篇 |
1983年 | 43篇 |
1982年 | 48篇 |
1981年 | 45篇 |
1980年 | 33篇 |
1979年 | 21篇 |
1978年 | 23篇 |
1977年 | 12篇 |
1976年 | 12篇 |
1974年 | 7篇 |
排序方式: 共有10000条查询结果,搜索用时 250 毫秒
51.
52.
53.
Joachim Fensterle 《Journal der Deutschen Dermatologischen Gesellschaft》2006,4(3):205-216
Many cellular signaling pathways are involved in the development of cancer. Depending on the tumor entity, the nature as well as the mode of activation can differ. Some signaling pathways frequently show changes as all tumor cells have to fulfill some basic requirements such as independence from growth factors or insensitivity against apoptosis. In this review, the possibilities of a tumor to manipulate signaling pathways to reach these goals are exemplified based on an archetypical melanoma cell. In addition, new therapeutic options based on the knowledge of signaling pathways will be discussed. 相似文献
54.
55.
Claudia Gedlicka Gudrun Hager Martina Weissenböck Wilhelm Gedlicka Birgit Knerer Johannes Kornfehl Michael Formanek 《Journal of oral pathology & medicine》2006,35(8):472-478
BACKGROUND: 1Alpha,25-dihydroxyvitamin D(3) [1,25(OH)(2) Vitamin D(3)] induces growth inhibition in squamous cell carcinoma (SCC) cell lines of the head and neck by arresting the cells in the G0/G1 phase of the cell cycle, probably due to an enhanced expression of p21, which could be demonstrated in other cell lines (JPPA, SCC9) before. In SCC25, a SCC cell line isolated from tongue, growth inhibition but no overexpression of p21 was detected. The retinoblastoma gene, as a direct target of G1 cyclin-CDK complexes, showed an obvious shift from the hyperphosphorylated to the hypophosphorylated form under 1,25(OH)(2)Vitamin D(3), which indicates that the growth inhibition takes place in the G0/G1 phase. To explore the possible pathway of growth inhibition in SCC25 we investigated other cell cycle inhibitors (p18, p19, p27). METHODS: Synchronized cells were treated with 1,25(OH)(2)Vitamin D(3) over 96 h. The cell cycle status and expression of cell cycle-regulating proteins was determined by fluorescence-activated cell sorting (FACS) and Western blotting. An overexpression of p18 in 1,25(OH)(2)Vitamin D(3) vs. ethanol-treated cells was determined until 30 h in SCC25. No influence was detectable on the expression of p27 and p19. CONCLUSION: One mechanism by which 1,25(OH)(2)Vitamin D(3) controls cell growth might be the upregulation of p21. As p21 was unsusceptible to 1,25(OH)(2)Vitamin D(3) in SCC25, other inhibiting proteins were necessary to be tested. The proven upregulation of p18 seems to be the responsible step for growth inhibition of 1,25(OH)(2)Vitamin D(3) in SCC25. 相似文献
56.
Pharmacokinetics and pharmacodynamics of benazepril hydrochloride in patients with major proteinuria
Ch. Schweizer G. Kaiser W. Dieterle J. Mann 《European journal of clinical pharmacology》1993,44(5):463-466
Summary We have investigated whether the pharmacokinetics and pharmacodynamics of the ACE inhibitor benazepril hydrochloride are altered with proteinuria by studying 8 patients with major proteinuria of different causes who were given a single dose of 10 mg p.o.The maximum plasma concentration of benazepril was found between 0.5 and 2 h after dosing (median 1 h). Its elimination was almost complete within 6 h. Peak plasma levels of benazeprilat, the active metabolite of benazepril, were observed between 1 and 6 h (median 2.5 h). The elimination of benazeprilat from plasma was biphasic, with mean initial and terminal half-lives of 3.0 and 17.3 h, respectively. On average, the pharmacokinetic parameters of benazepril and benazeprilat in the patients did not differ from those in a historical control group of healthy volunteers, but intersubject variability in the AUC and half-lives of benazeprilat was greater in the patients.Plasma ACE was completely inhibited from 1.5 to 6 h after dosing, and at 48 h the mean inhibition was still 42 %. Plasma renin showed substantial intersubject variation. Mean supine blood pressure (systolic/diastolic) was reduced from baseline by a maximum of 18/13 mm Hg at 6 h. Proteinuria was diminished after benazepril in 7 patients.In conclusion, the results of this study suggest that proteinuria in the nephrotic range does not require a change in benazepril dosage. 相似文献
57.
A RELIABLE MARKER OF ENDOTHELIAL CELL DYSFUNCTION: DOES IT EXIST? 总被引:19,自引:0,他引:19
58.
D J Bowen 《Journal of clinical pathology》2002,55(1):1-18
This review focuses on selected areas that should interest both the scientist and the clinician alike: polymorphisms within the factor VIII and factor IX genes, their linkage, and their ethnic variation; a general assessment of mutations within both genes and a detailed inspection of the molecular pathology of certain mutations to illustrate the diverse cause–effect relations that exist; a summary of current knowledge on molecular aspects of inhibitor production; and an introduction to the new areas of factor VIII and factor IX catabolism. An appendix defining various terms encountered in the molecular genetics of the haemophilias is included, together with an appendix providing accession numbers and locus identification links for accessing gene and sequence information in the international nucleic acid databases. 相似文献
59.
钾通道阻断剂对低氧/复氧诱导的培养海马神经元死亡的防护作用 总被引:3,自引:0,他引:3
目的研究钾通道阻断剂对单纯低氧/复氧诱导的培养海马神经元死亡的防护作用。方法培养8 d的海马神经元置于低氧环境(95% N2/5% CO2)6 h,复氧再培养直至72 h,复氧后0.5 h培养液内分别给予不同钾通道阻断剂,用细胞计数及MTT比色法检测神经元死亡情况。结果低氧/复氧诱导培养海马神经元出现迟发性死亡;四乙铵以剂量依赖性的方式防护低氧/复氧诱导的培养海马神经元免于死亡;大电导钙激活钾通道(BK通道)阻断剂iberiotoxin(IbTX)可完全消除低氧/复氧诱导的神经元死亡(P<0.001);A型钾通道阻断剂4-氨基吡啶不能防护低氧/复氧诱导的神经元免于死亡(P>0.05)。结论钾通道阻断剂四乙铵和IbTX能防护低氧/复氧诱导的培养海马神经元免于死亡,提示某些类型的钾通道尤其是BK通道活动增强可能参与了低氧/复氧诱导的培养海马神经元死亡。 相似文献
60.
MMP-9和TIMP-1表达失衡与乳腺癌浸润、转移的相关性 总被引:2,自引:0,他引:2
目的 研究乳腺癌组织中基质金属蛋白酶(MMP-9)和金属蛋白酶组织抑制因子(TIMP-1)的表达变化与乳腺癌生物学行为及淋巴结转移的关系。方法 应用SP免疫组织化学方法检测85例乳腺癌组织MMP-9,TIMP-1及细胞增殖核抗原ki-67的表达情况。结果 MMP-9阳性染色率90.59%,MMP-9阳性表达与肿瘤浸润,淋巴结转移,ki-67指数及TNM分期呈正相关(Pearson列联系数分别为P=0.03,P=0.02,P=0.004和P=0.0000,P<0.05,0.01。TIMP-1阳性染色率为78.82%,TIMP-1阳性表达与肿瘤浸润,淋巴结转移及TNM分期浸润,转移及ki-67指数显著相关(P<0.05,P<0.01,P<0.001)。结论 MMP-9和TIMP-1表达失衡与乳腺癌浸润及淋巴结转移密切相关。 相似文献